NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
uniQure N.v. QURE
12 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$16.1M
▼ 40.6% vs FY2024
EPS · FY25
$-3.46
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-207.1%
Net margin · FY25
-1236.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 16.1M
Revenue, FY2025 · full 12-year series below
Revenue
Net income
The company lost 1236 cents on every revenue dollar this year.
Per share
USD -3.46
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-207.1%
Return on equity, FY2025
ROE
Operating margin-1151.4%
Net margin-1236.0%
Return on assets-28.8%
Each USD of equity lost 207 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−15.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−46.7%
−15.6%
+4.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years+39.2%
Change, 10 years+156.2%
The share count grew 39% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 824.9M
total assets, end of FY2025
Total assetsUSD 824.9M
EquityUSD 198.9M
CashUSD 80.2M
Gross debtUSD 49.7M
Net debtUSD -30.5M
Current ratio10.43×
The company holds more cash than debt.
History
12 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue $B
0.0
0.0
0.0
0.1
0.5
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.2
−0.2
−0.3
−0.1
0.3
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
EBITDA $B
−0.2
−0.2
−0.3
−0.1
0.3
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
Income tax $B
0.0
0.0
0.0
−0.0
0.0
−0.0
·
0.0
−0.0
0.0
−0.0
−0.0
Net income $B
−0.2
−0.2
−0.3
−0.1
0.3
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
EPS, diluted $
−3.46
−4.92
−6.47
−2.71
7.04
−2.81
−3.11
−2340.00
−2940.00
−2.93
−3.72
−2.91
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−207.1
−238.5
−90.2
−23.7
78.5
−44.1
−49.4
−61.9
−103.6
−76.6
−96.3
−116.8
Shares out B
0.06
0.05
0.05
0.05
0.05
0.04
0.04
0.04
0.03
0.03
0.02
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
34 of 34
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed